Antibodies in action: Role of human opsonins in killing Salmonella enterica serovar Typhi

Infection and Immunity

Volumn 79, Issue 8, 2011, Pages 3188-3194

  Lindow, Janet C ^a   Fimlaid, Kelly A ^a   Bunn, Janice Y ^b   Kirkpatrick, Beth D ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b University of Vermont   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN; M01ZH09; OPSONIN; PLACEBO; UNCLASSIFIED DRUG; VACCINE;

ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; ASSAY; BACTERICIDAL ACTIVITY; BACTERICIDAL ASSAY; COMPLEMENT FACTOR; HUMAN; IMMUNOGENICITY; MACROPHAGE; PRIORITY JOURNAL; SALMONELLA TYPHI; SURVIVAL; TYPHOID FEVER; VACCINATION; WILD TYPE;

ADULT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; HUMANS; MACROPHAGES; MICROBIAL VIABILITY; OPSONIN PROTEINS; PHAGOCYTOSIS; SALMONELLA TYPHI; TYPHOID-PARATYPHOID VACCINES;

EID: 79961124827     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05081-11     Document Type: Article

References (51)

1. Bhutta, Z. A. 1996. Impact of age and drug resistance on mortality in typhoid fever. Arch. Dis. Child. 75:214-217.
2. Bhutta, Z. A., and J. Threlfall. 2009. Addressing the global disease burden of typhoid fever. JAMA 302:898-899.
3. Biozzi, G., C. Stiffel, B. N. Halpern, L. Le Minor, and D. Mouton. 1961. Measurement of the opsonic effect of normal and immune sera on the phagocytosis of Salmonella Typhi by the reticuloendothelial system. J. Immunol. 87:296-300.
4. Canh, D. G., et al. 2004. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect. Immun. 72:6586-6588.
5. Clemens, J. D., et al. 1991. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J. Infect. Dis. 163:1235-1242.
6. Crump, J. 2004. The global burden of typhoid fever. Bull. World Health Organ. 82:346-353.
7. Cryz, S. J., Jr., E. Furer, and M. M. Levine. 1988. Effectiveness of oral, attenuated live Salmonella typhi Ty 21a vaccine in controlled field trials. Schweiz. Med. Wochenschr. 118:467-470.
8. Cryz, S. J., Jr., et al. 1993. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect. Immun. 61:1149-1151.
9. D'Amelio, R., et al. 1988. Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines. Infect. Immun. 56:2731-2735.
10. Dragunsky, E. M., E. Rivera, H. D. Hochstein, and I. S. Levenbook. 1990. In vitro characterization of Salmonella typhi mutant strains for live oral vaccines. Vaccine 8:263-268.
11. Dragunsky, E. M., C. R. Wooden, S. A. Vargo, and I. S. Levenbook. 1989. Salmonella typhi vaccine strain in vitro; low infectivity in human cell line U937. J. Biol. Stand. 17:353-360.
12. Drecktrah, D., L. A. Knodler, R. Ireland, and O. Steele-Mortimer. 2006. The mechanism of Salmonella entry determines the vacuolar environment and intracellular gene expression. Traffic 7:39-51.
13. Engels, E. A., M. E. Falagas, J. Lau, and M. L. Bennish. 1998. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 316:110-116.
14. Fraser, A., M. Paul, E. Goldberg, C. J. Acosta, and L. Leibovici. 2007. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 25:7848-7857.
15. Galen, J. E., et al. 2009. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol. Cell Biol. 87:400-412.
16. Glass, R. I., et al. 1985. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J. Infect. Dis. 151:236-242.
17. Hohmann, E. L., C. A. Oletta, K. P. Killeen, and S. I. Miller. 1996. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic singledose typhoid fever vaccine in volunteers. J. Infect. Dis. 173:1408-1414.
18. Ishibashi, Y., and T. Arai. 1996. A possible mechanism for host-specific pathogenesis of Salmonella serovars. Microb. Pathog. 21:435-446.
19. Jack, D. L., et al. 1998. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J. Immunol. 160: 1346-1353.
20. Keitel, W. A., N. L. Bond, J. M. Zahradnik, T. A. Cramton, and J. B. Robbins. 1994. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 12:195-199.
21. -) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 24:116-123.
22. Kirkpatrick, B. D., et al. 2005. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J. Infect. Dis. 192:360-366.
23. Klugman, K. P., H. J. Koornhof, J. B. Robbins, and N. N. Le Cam. 1996. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14:435-438.
24. Levine, M. M., et al. 1999. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 17(Suppl. 2):S22-S27.
25. Levine, M. M., C. Ferreccio, S. Cryz, and E. Ortiz. 1990. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 336:891-894.
26. Levine, M. M., D. Hone, C. Tacket, C. Ferreccio, and S. Cryz. 1990. Clinical and field trials with attenuated Salmonella typhi as live oral vaccines and as "carrier" vaccines. Res. Microbiol. 141:807-816.
27. Levine, M. M., C. O. Tacket, and M. B. Sztein. 2001. Host-Salmonella interaction: human trials. Microbes Infect. 3:1271-1279.
28. Lin, F. Y., et al. 2001. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344:1263-1269.
29. Losonsky, G. A., et al. 1996. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect. Immun. 64:10-15.
30. Lundgren, A., J. Kaim, and M. Jertborn. 2009. Parallel analysis of mucosally derived B- and T-cell responses to an oral typhoid vaccine using simplified methods. Vaccine 27:4529-4536.
31. Lyon, C. E., et al. 2010. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units. Vaccine 28:3602-3608.
32. Mai, N. L., et al. 2003. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N. Engl. J. Med. 349:1390-1391.
33. Mousa, G. Y., J. R. Trevithick, J. Bechberger, and D. G. Blair. 1978. Cytochalasin D induces the capping of both leukaemia viral proteins and actin in infected cells. Nature 274:808-809.
34. Olanratmanee, T., M. Levine, G. Losonsky, V. Thisyakorn, and S. J. Cryz, Jr. 1992. Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4- to 6-year-old Thai children. J. Infect. Dis. 166:451-452.
35. Pegues, D. A., M. E. Ohl, and S. I. Miller. 2004. Salmonella species, including Salmonella Typhi, p. 2636-2653. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious disease. Churchill-Livingstone, Philadelphia PA.
36. Pulickal, A. S., et al. 2009. Kinetics of the natural, humoral immune response to Salmonella enterica Serovar Typhi in Kathmandu, Nepal. Clin. Vaccine Immunol. 16:1413-1419.
37. Rowe, B., L. R. Ward, and E. J. Threlfall. 1997. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clin. Infect. Dis. 24(Suppl. 1):S106-S109.
38. Stratford, R., et al. 2005. Optimization of Salmonella enterica serovar typhi DeltaaroC DeltassaV derivatives as vehicles for delivering heterologous antigens by chromosomal integration and in vivo inducible promoters. Infect. Immun. 73:362-368.
39. Sur, D., et al. 2009. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N. Engl. J. Med. 361:335-344.
40. Sztein, M. B. 2007. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans. Clin. Infect. Dis. 45(Suppl. 1):S15-S19.
41. Tacket, C. O., and M. M. Levine. 2007. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin. Infect. Dis. 45(Suppl. 1):S20-S23.
42. Tagliabue, A., et al. 1985. Cellular immunity against Salmonella typhi after live oral vaccine. Clin. Exp. Immunol. 62:242-247.
43. Tagliabue, A., et al. 1986. IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine. J. Immunol. 137:1504-1510.
44. Tam, M. A., A. Rydstrom, M. Sundquist, and M. J. Wick. 2008. Early cellular responses to Salmonella infection: dendritic cells, monocytes, and more. Immunol. Rev. 225:140-162.
45. Tobar, J. A., P. A. Gonzalez, and A. M. Kalergis. 2004. Salmonella escape from antigen presentation can be overcome by targeting bacteria to Fc gamma receptors on dendritic cells. J. Immunol. 173:4058-4065.
46. Tran, T. H., et al. 2010. A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. PLoS One 5:e11778.
47. Wahid, R., et al. 2011. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27(+)IgD(-) S. Typhi-specific IgA and IgG B memory cells in humans. Clin. Immunol. 138:187-200.
48. Wasserman, S. S., et al. 1994. Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine 12:1000-1003.
49. WHO. 2003. posting date. Background document: the diagnosis, treatment and prevention of typhoid fever. WHO WHO/V&B/03.07. http://www.who.int/vaccines-documents.
50. Wick, M. J. 2007. Monocyte and dendritic cell recruitment and activation during oral Salmonella infection. Immunol. Lett. 112:68-74.
51. Wilson, R. P., et al. 2011. The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of Salmonella enterica serotype Typhi. Infect. Immun. 79:830-837.